NCT01721577View on ClinicalTrials.gov

Phase I/II Trial of AXL1717 in the Treatment of Recurrent Malignant Astrocytomas

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions
GlioblastomaGliosarcomaAnaplastic AstrocytomaAnaplastic OligodendrogliomaAnaplastic OligoastrocytomaAnaplastic Ependymoma
Interventions
DRUG

AXL1717

IGF-1 receptor inhibitor

Trial Locations (1)

60612

Rush University Medical Center, Chicago

Sponsors

Collaborators (1)

Axelar AB
All Listed Sponsors
collaborator

Axelar AB

INDUSTRY

lead

Rush University Medical Center

OTHER

NCT01721577 - Phase I/II Trial of AXL1717 in the Treatment of Recurrent Malignant Astrocytomas | Biotech Hunter | Biotech Hunter